This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
On October 29, 2009, the Philippine television network GMA News and Public Affairs, producers of Wish Ko Lang ("Just My Wish") hosted by Vicky Morales, profiled the story of Pilma Cabrijas, a 30-year-old woman affected by gigantomastia. The woman was told by a folk healer that her condition may have been caused by a curse. The measured bust circumference without appropriate bra support was 160 cm (63 in). The weight of her breasts was not reported in detail, but seemed to weigh "as much as two children." She had breast reduction surgery performed, but her breasts regrew. The producers of Wish Ko Lang paid for additional surgery.
Coal and oil are possible examples of constituents which may have undergone changes over geologic time periods. Chalk and limestone are examples of secretions (marine animal shells) which are of geologic age. Grass and wood are biogenic constituents of contemporary origin. Pearls, silk and ambergris are examples of secretions of contemporary origin. Biogenic neurotransmitters.
13 October A grenade was thrown in the Vi Thanh District Chieu Hoi center, killing three civilians and wounding 46. The VC kidnapped a Catholic priest and a lay assistant, from the church at Phu Hoi, Biên Hòa Province.
== Philanthropy == In April 2017, Metropolis launched a scholarship and mentorship program, called "Medengage", for undergraduate and postgraduate medical students across India. In July 2017, Metropolis and the PCOS Society of India launched a Polycystic Ovarian Syndrome (PCOS) awareness campaign called "Conquer PCOS". In August 2018, Metropolis initiated an "Umbrella Handshake" campaign to create awareness about health. The company donated ₹2 million (equivalent to ₹2.9 million or US$30,000 in 2026) towards this and other social welfare initiatives. Metropolis partnered with We Foundation and Red FM, to help in public outreach and campaign awareness.
Sources: en.wikipedia.org
== Administration == Rivastigmine tartrate is a white to off-white, fine crystalline powder that is both lipophilic (soluble in fats) and hydrophilic (soluble in water). It comes in a variety of administrations including a capsule, solution and a transdermal patch. Like other cholinesterase inhibitors, it requires doses to be increased gradually over several weeks; this is usually referred to as the titration phase.
Silk has been used to close wounds for centuries. By the 19th and 20th centuries it had become one of the standard suture materials in Western surgery—strong, easy to handle and reliable at holding a knot—and braided silk remained in use long after many other natural threads had given way to synthetics. The field in its current form began with a straightforward idea: silk could be broken down and then reassembled into a new form. Dissolving degummed fibres in a concentrated salt solution yields a water-based fibroin liquid that can be cast, spun or gelled. This regenerated silk, rather than the woven fibre, is the basis of most silk biomaterials. The methods for preparing the solution and converting it into films, sponges and hydrogels were established in the late 1990s and 2000s, much of the work carried out at Tufts University in the United States. A 2010 review in Science described how regenerated silk had extended beyond textiles and sutures into optics, electronics and tissue engineering, and helped establish its reputation as a material that can be processed from water under mild conditions. The first engineered silk devices received regulatory clearance in the same period, marking the point at which laboratory research began to yield commercial products.
Hancock, David (2001). The Mastiffs: The Big Game Hunters – Their History, Development and Future. Ducklington, Oxon: Charwynne Dog Features. ISBN 9780951780114. Fogle, Bruce (2009). The Encyclopedia of the Dog. New York: DK Publishing. ISBN 978-0-7566-6004-8. Encyclopædia Britannica (2019). "Mastiff: breed of dog". www.britannica.com. Encyclopædia Britannica, Inc. Retrieved 9 September 2019. Parker, Heidi G. (2012). "Chapter 3: The history and relationship of dog breeds". In Ostrander, Elaine A.; Ruvinsky, Anatoly (eds.). The Genetics of the Dog. Wallingford, Oxfordshire: CAPI books. pp. 38–53. ISBN 9781845939403. Oxford Dictionaries (2019). "Mastiff". Lexico.com. Oxford University Press. Retrieved 9 September 2019. Wynn, M. B. (1886). History of the Mastiff: Gathered from Sculpture, Pottery, Carvings, Paintings and Engravings. Melton Mowbray, William Loxley. ISBN 978-1-4465-4892-9. {{cite book}}: ISBN / Date incompatibility (help) Young, Amy; Bannasch, Danika (2007). "Chapter 4: Morphological variation in the dog". In Ostrander, Elaine A.; Giger, Urs; Lindblad-Toh, Kerstin (eds.). The Dog and its Genome. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. pp. 47–66. ISBN 9780879697815.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.